VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Psoriasis
Conditions
Psoriasis
Trial Timeline
Nov 17, 2022 → Dec 20, 2023
NCT ID
NCT05655299About VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + Placebo
VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + Placebo is a phase 2 stage product being developed by Ventyx Biosciences for Psoriasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT05655299. Target conditions include Psoriasis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05655299 | Phase 2 | Terminated |
Competing Products
20 competing products in Psoriasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ixekizumab + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo Subcutaneous | Eli Lilly | Phase 2 | 52 |
| Ixekizumab | Eli Lilly | Phase 3 | 77 |
| 80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + Placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + Baricitinib | Eli Lilly | Phase 2 | 52 |
| CT-P43 + Stelara | Celltrion | Phase 3 | 77 |
| CT-P17 + EU-approved Humira | Celltrion | Phase 3 | 77 |
| CT-P55 + EU-approved Cosentyx | Celltrion | Phase 3 | 77 |
| AMG 139 | AstraZeneca | Phase 1 | 33 |
| alefacept + polyvalent pneumococcal vaccine | Astellas Pharma | Approved | 85 |
| alefacept | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus Cream | Astellas Pharma | Phase 3 | 77 |
| alefacept | Astellas Pharma | Phase 3 | 77 |
| peficitinib + Placebo | Astellas Pharma | Phase 2 | 52 |
| Alefacept | Astellas Pharma | Phase 3 | 77 |
| Amevive exposure | Astellas Pharma | Pre-clinical | 23 |
| alefacept + placebo | Astellas Pharma | Phase 3 | 77 |
| alefacept | Astellas Pharma | Approved | 85 |
| ASKP1240 + Placebo | Astellas Pharma | Phase 2 | 52 |
| Tacrolimus Cream | Astellas Pharma | Phase 3 | 77 |